drugset / Trial / NCT00375050

Treatment of Refractory Schizophrenia With Riluzole

NCT00375050

RandomizedParallel-groupDouble-blindTreatment

Summary

The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms. Neuroprotective medication riluzole is currently approved for treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease), a severe neurological illness. Due to its unique mechanism of action, riluzole, if effective in helping the symptoms of schizophrenia, would open novel directions in treatment of schizophrenia.

Timeline

Start
2002-05
Primary completion
2006-08-29
Completion
2006-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Riluzole Small molecule